BiomX’s (PHGE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of BiomX (NYSEMKT:PHGE) in a research note published on Friday morning,Benzinga reports. They currently have a $21.00 price target on the stock. HC Wainwright also issued estimates for BiomX’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.

BiomX Stock Performance

BiomX has a 12 month low of $0.48 and a 12 month high of $4.99. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The business has a fifty day moving average of $0.71 and a 200-day moving average of $0.75. The company has a market capitalization of $13.89 million, a P/E ratio of -0.76 and a beta of 1.38.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. acquired a new position in shares of BiomX in the 4th quarter valued at approximately $632,000. Allostery Investments LP acquired a new position in BiomX in the 4th quarter worth $470,000. Finally, JPMorgan Chase & Co. bought a new position in BiomX during the 4th quarter worth about $314,000. Institutional investors and hedge funds own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.